| Followers | 905 |
| Posts | 39732 |
| Boards Moderated | 7 |
| Alias Born | 03/22/2016 |
Tuesday, January 21, 2025 10:42:15 AM
AKBA test that 2.50 from a year ago
Recent AKBA News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 11:24:30 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 11:05:53 AM
- Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights • GlobeNewswire Inc. • 05/07/2026 11:00:00 AM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/04/2026 08:05:00 PM
- Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology • GlobeNewswire Inc. • 05/04/2026 12:00:00 PM
- Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights • GlobeNewswire Inc. • 04/30/2026 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 08:13:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 08:12:53 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/15/2026 08:08:50 PM
- Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 • GlobeNewswire Inc. • 04/13/2026 12:00:00 PM
- Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium • GlobeNewswire Inc. • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:06:54 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:05:32 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 08:48:09 PM
- Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors • GlobeNewswire Inc. • 04/01/2026 08:05:00 PM
- Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 • GlobeNewswire Inc. • 03/19/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 11:55:46 PM
- Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference • GlobeNewswire Inc. • 03/03/2026 01:00:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/02/2026 09:05:00 PM
- Akebia Therapeutics posts mixed Q4 results as revenue beats expectations despite EPS miss • IH Market News • 02/26/2026 03:57:19 PM
- Akebia tops Q4 revenue expectations as Vafseo momentum strengthens outlook • IH Market News • 02/26/2026 03:48:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:04:39 PM
- Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
- Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights • GlobeNewswire Inc. • 02/19/2026 01:00:00 PM
